Thu. 2 Jun 2022, 6:37am ET Benzinga News, Global

ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with Juvenis to conduct cross-border sales of Tru Niagen® in South Korea. Juvenis is a Korean healthcare marketing company with a focus on the cosmetic and dietary supplement industries. With strong partnerships in a dynamic and trend-setting Korean market, Juvenis emphasizes products with differentiated science and proven benefits.

Tru Niagen® is one of Amazon’s top-selling brands in the Vitamin B3 category for boosting NAD+ levels and features ChromaDex’s proprietary ingredient, Niagen® (patented nicotinamide riboside or NR). Between 2019 and 2050, the Republic of Korea is expected to experience the highest increase in its share of older persons, with a 23% increase in those 65 years or older. Nine out of the 10 countries with the largest percentage increase in the share of older persons in the world will be in Eastern and South-Eastern Asia (United Nations).

“As a pioneer of NAD+ research, we are committed to helping communities abroad discover the benefits of cellular energy, defense, repair, and vitality as they age. It is our goal to provide global access to Tru Niagen® and are thrilled to partner with Juvenis to bring its proven benefits to South Korea,” said Frank Jaksch, Co-Founder and Executive Chairman of ChromaDex.

Just this April 2022, Dr. Charles Brenner (Alfred E Mann Family Foundation Chair in Diabetes and Cancer Metabolism at City of Hope National Medical Center and ChromaDex Chief Scientific Advisor) spoke about innovations in metabolism, including the importance of NR, at K.E.Y. Platform in Seoul, South Korea.

Tru Niagen® will be available for sale in the South Korean market on several cross-border marketplaces including NaverSmartStore, 11thStreet, kakaoStore, Gmarket, Auction, and will also be available on www.TruNiagenKorea.com.

“We are pleased to execute a partnership with ChromaDex for the South Korean market,” said Dongyeon Kim, CEO of Juvenis. “With a strong collaboration between ChromaDex and Juvenis, we look forward to building a prosperous long-term business together. Above all, we are looking forward to working with ChromaDex to help the Korean community age healthier.”

NR, the key ingredient in Tru Niagen®, is the world’s most efficient NAD+ precursor on the market, particularly over NMN (nicotinamide mononucleotide). Supplementation with Niagen® is backed by 20 published and peer-reviewed clinical trials. Niagen® has achieved regulatory acceptance for use in supplements by the US FDA. Additionally, Niagen® has been approved for use in food supplements by the European Commission, complementary medicines by the Therapeutic Goods Administration of Australia (TGA), medical foods by the Brazilian Health Regulatory Agency (ANVISA), and medical foods by the Food Standards Australia New Zealand (FSANZ). Tru Niagen® has also been approved by Health Canada as a Natural Health Product. Additionally, ChromaDex continues to lead the industry in NAD+ research and recently announced that the ChromaDex External Research Program (CERPTM) reached over 250 material transfer agreements (MTAs) featuring Niagen® and other proprietary ingredients.

For additional information on the science supporting Niagen® visit www.chromadex.com.